id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2009-0007,FDA,FDA-2022-E-2009,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-27T05:00:00Z,2025,1,2025-01-27T05:00:00Z,,2025-01-27T16:57:37Z,,0,0,09000064868ffc56
FDA-2022-E-2009-0006,FDA,FDA-2022-E-2009,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-02-27T05:00:00Z,2024,2,2024-02-27T05:00:00Z,,2024-02-27T15:44:06Z,,0,0,09000064863e550b
FDA-2022-E-2009-0005,FDA,FDA-2022-E-2009,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:11:49Z,,0,0,0900006486365c63
FDA-2022-E-2009-0004,FDA,FDA-2022-E-2009,Determination of Regulatory Review Period for Purposes of Patent Extension; LYBALV,Notice,Determinations,2023-12-21T05:00:00Z,2023,12,2023-12-21T05:00:00Z,2024-02-21T04:59:59Z,2023-12-21T15:26:24Z,2023-28094,0,0,090000648634e3d3
FDA-2022-E-2009-0003,FDA,FDA-2022-E-2009,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-28T04:00:00Z,2022,9,2022-09-28T04:00:00Z,,2022-09-28T20:26:17Z,,0,0,090000648537b1d2
FDA-2022-E-2009-0001,FDA,FDA-2022-E-2009,Letter from U S Patent and Trademark Office,Other,Letter(s),2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T13:32:19Z,,0,0,0900006485273371
FDA-2022-E-2009-0002,FDA,FDA-2022-E-2009,"Patent Term Extension Application for LYBALVI® Patent No 7,262,298",Other,Application,2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T13:34:02Z,,0,0,090000648527348d